3bigs and AWS partner to build a bio-health big data platform
Category: #health  By Vikas M  Date: 2021-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

3bigs and AWS partner to build a bio-health big data platform

Korean bio-venture, 3bigs, has recently announced developing a big data platform for genome therapy and drug development in association with Amazon Web Services (AWS).

As per credible sources, 3bigs will be working with Amazon Web Services to build a bio-health data platform. The bio-health big data platform will combine patient data and genomic data of the main hospitals in Busan, Korea's second-largest city.

Apparently, it can be done by leveraging AWS services that offer access control to patients' information, allowing doctors and the diagnostic labs to explore the clinical reports safely.

Under the agreement, 3bigs plan to build a research platform for drug and genome therapy development by actively utilizing AWS services for integrated bio-health information and analyzing disease linkage, using the hospital patient and genomic data.

As per company officials, with the help of this platform, the main hospitals in Busan, including Pusan National University Hospital, will find accurate treatment methods for patients who have cancer and other rare diseases.

The platform also provides the data from patients with genomic mutations identical to those of patients and clinical results obtained from chemotherapy to develop the new drug. Additionally, it can also reduce many side effects by recognizing effects that do not match the patient's genetic information during chemotherapy or the risk of using other medical drugs.

Moreover, AWS will help 3bigs in recommending a cloud-based genome research platform to the government of Korea leveraging its service's secure, flexible research environment, cost-effective, and aid 3bigs in moving its genome research solution to the AWS Cloud.

3bigs CEO, Park Joon-Hyung, commented that by using AWS's wide-ranging and in-depth services with the maximum-security standards, the firm would potentially integrate bio-health solutions to advance healthcare. Their expertise will contribute to bio-health projects at home and abroad and rejuvenate the future of the healthcare industry.

Source Credit - https://www.koreabiomed.com/news/articleView.html?idxno=12700

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Vikas M    

...

Read More

More News By Vikas M

WHO: novel drugs may support fight against COVID-19 in 2022
WHO: novel drugs may support fight against COVID-19 in 2022
By Vikas M

World Health Organisation’s (WHO) Regional Director for Europe, Hans Kluge has reportedly stated that new drugs developed against COVID-19 will intensify the survival rate for patients suffering from severe COVID conditions in 2022. The Europe...

France’s deal with Merck for Covid antiviral drug collapses post trial
France’s deal with Merck for Covid antiviral drug collapses post trial
By Vikas M

The French health authority has been reluctant to authorize Merck’s Covid antiviral pill France has called off its order for Covid antiviral drug developed by American pharmaceutical giant Merck following unsatisfactory trial results. Accord...

Byju's to go public through a SPAC deal; aims $48 billion valuation
Byju's to go public through a SPAC deal; aims $48 billion valuation
By Vikas M

Indian edtech company, Byju's is reportedly involved in advance talks for going public via a merger with one of Churchill Capital's special-purpose acquisition companies. Sources cite that the startup has had talks with many potential SPAC p...